Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.
Analyst Upgrades and Downgrades
RCDTF has been the topic of several recent research reports. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a "hold" rating in a report on Monday, October 7th. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a "strong sell" rating in a research report on Tuesday, October 22nd.
Read Our Latest Report on RCDTF
Recordati Industria Chimica e Farmaceutica Price Performance
The stock has a market cap of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33. The company's 50 day moving average price is $52.20 and its two-hundred day moving average price is $52.03. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73.
Recordati Industria Chimica e Farmaceutica Company Profile
(
Get Free Report)
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recordati Industria Chimica e Farmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recordati Industria Chimica e Farmaceutica wasn't on the list.
While Recordati Industria Chimica e Farmaceutica currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
